Article in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 3 institutions in 2 countries.
Ceyda Tuna KırsaçlıoğluDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Ankara University School of Medicine, Ankara, Türkiye, Turkey. ckirsaclioglu@ankara.edu.tr.ORCID 0000-0002-3551-7267
Alexandra FrohneSt. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.ORCID 0000-0001-6641-4001
Zarife KuloğluDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0001-9442-7790
Isidora KristofersdottirSt. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
Engin DemirDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0001-6263-5915
Cansu AltuntaşDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0002-1161-5145
Zehra Şule HaskoloğluDepartment of Pediatrics, Division of Pediatric Immunology and Allergy, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0002-2668-0441
Fatma Nazan ÇobanoğluDepartment of Pediatrics, Division of Pediatric Pulmonology, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0002-3686-2927
Tanıl KendirliDepartment of Pediatrics, Division of Pediatric Intensive care, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0001-9458-2803
Halil ÖzdemirDepartment of Pediatrics, Division of Pediatric Infectious Disease, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0002-7318-1688
Zeynep Birsin ÖzçakarDepartment of Pediatrics, Division of Pediatric Nephrology and Rheumotology, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0002-6376-9189
Berna SavaşDepartment of Pathology, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0003-3971-1419
Figen DoğuDepartment of Pediatrics, Division of Pediatric Immunology and Allergy, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0002-7869-4941
Aydan İkincioğullarıDepartment of Pediatrics, Division of Pediatric Immunology and Allergy, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0003-1145-0843
Kaan BoztugSt. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.ORCID 0000-0001-8387-9185
Aydan KansuDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Ankara University School of Medicine, Ankara, Türkiye, Turkey.ORCID 0000-0002-3133-9846
Ankara University · TRSt Anna Children's Hospital · ATAustrian Academy of Sciences · AT
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The monogenic causes of very-early-onset inflammatory bowel disease (VEO-IBD) have been defined by genetic studies, which were usually related to primary immunodeficiencies. Receptor-interacting serine/threonine-protein kinase-1 (RIPK1) protein is an important signalling molecule in inflammation and cell death pathways. Its deficiency may lead to various clinical features linked to immunodeficiency and/or inflammation, including IBD. Here, we discuss an infant with malnutrition, VEO-IBD, recurrent infections and polyathritis who has a homozygous partial deletion in RIPK1 gene.
Indexed as
Gene DeletionInflammatory Bowel DiseasesReceptor-Interacting Protein Serine-Threonine KinasesAge of OnsetHumansInfantMaleReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanImmunodefciencyInflammationVery-early Onset Inflammatory Bowel Disease
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Very-early-onset Inflammatory Bowel Disease in an Infant with a Partial RIPK1 Deletion. · full record | OpenQuestion